BOLT SHAREHOLDER ALERT: Edelson Lechtzin LLP Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Shareholders to Consult Legal Counsel About the Pending Securities Fraud Class Action

To be considered for a lead plaintiff role, a Bolt investor must file a motion in the U.S. District Court for the Northern District of California, no later than September 3, 2024. Please contact Edelson Lechtzin LLP to discuss your investment losses, at 844-696-7492 or by e-mail at [email protected]. You can also submit your trading information online HERE. Background on Bolt Biotherapeutics, Inc. focused on developing immunotherapies for cancer treatment, primarily through its "Boltbody" pipeline. The Bolt ...